Human rabies immunoglobulin (HRIG)
Rabies immunoglobulin
Brand names: HyperRAB, Imogam
Adult dose
Dose: 20 IU/kg infiltrated around wound (remainder IM distant from vaccine site)
Route: Wound infiltration / IM
Frequency: single (post-exposure)
Clinical pearls
- Rabies post-exposure prophylaxis (Category III) in non-immunised — with vaccine
- UKHSA Green Book Ch.27
Contraindications
- IgA deficiency (severe)
- Hypersensitivity
Side effects
- Injection-site reactions
- Fever
- Anaphylaxis (rare)
Interactions
- Live vaccines (within 3 months — reduced efficacy)
Reference: BNF; UKHSA Green Book Ch.27; https://bnf.nice.org.uk/drugs/rabies-immunoglobulin/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023